Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model

Norikazu Tanabe,¹ Taro Takami,¹,* Koichi Fujisawa,a,² Toshihiko Matsumoto,¹,3 Naoki Yamamoto¹,4 and Isao Sakaida¹

¹Department of Gastroenterology and Hepatology, ²Center of Research and Education for Regenerative Medicine and ³Department of Oncology & Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755-8505, Japan
⁴Yamaguchi University Health Administration Center, 1677-1 Yoshida, Yamaguchi, Yamaguchi 753-8511, Japan

(Received 21 December, 2016; Accepted 25 January, 2017; Published online 16 May, 2017)

Spironolactone and furosemide, which are used to treat ascites associated with decompensated cirrhosis, are ineffective in treating refractory ascites. Hence, combination therapy with tolvaptan, a vasopressin V2 receptor antagonist, has been approved in Japan. Tolvaptan monotherapy and combination therapy with furosemide inhibit fibrosis in cardiac remodeling; hence, we examined these therapies in a rat cirrhotic model, including their usefulness in inhibiting hepatic fibrosis. In the present study, we used a model of hepatic fibrosis induced by a choline-deficient l-amino-acid-defined diet + diethylnitrosamine. Rats were divided into a low-dose furosemide group (15 mg/kg/day), a high-dose furosemide group (100 mg/kg/day), a tolvaptan monotherapy group (10 mg/kg/day), a low-dose furosemide/tolvaptan combination therapy group, and a control group which received neither furosemide nor tolvaptan; we then assessed diuretic effects and hepatic fibrosis. The tolvaptan monotherapy group and the furosemide/tolvaptan combination therapy group demonstrated significantly higher urine volume than the control group and the low-dose furosemide group. In addition, tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy were found to inhibit hepatic fibrosis and yield a hepatoprotective effect by an antioxidative mechanism. The results of the present study suggest that tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy are highly effective for hepatoprotection and diuresis.

Key Words: tolvaptan, furosemide, liver fibrosis, hepatoprotection, diuresis

Cirrhosis patients frequently demonstrate hepatic edema as a clinical symptom of decreased liver function. Persistent subjective and objective symptoms associated with hepatic edema reduce quality of life.(1) Ascites associated with decompensated cirrhosis have long been treated with drugs such as spironolactone and furosemide.(2) However, there are cases of refractory ascites in which these drugs have often failed to yield appreciable therapeutic effects, even when used in combination.(3) Tolvaptan, a vasopressin V2 receptor antagonist, can be used to treat hyponatremia, hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion, and fluid retention resulting from heart failure.(4) Previously, we reported that tolvaptan improves hepatic edema and ascites,(5) and is approved in Japan for the treatment of refractory ascites in cirrhosis. Because tolvaptan exhibits a diuretic effect without excretion of sodium, it may be used in combination therapy to treat fluid retention in cirrhosis when existing diuretics fail to achieve a sufficient therapeutic effect.

A few studies in cardiovascular medicine have shown that in rat models of acute and chronic myocardial infarction, tolvaptan monotherapy and combination therapy with furosemide inhibit fibrosis in cardiac remodeling.(6,7) Fascinatingly, tolvaptan has also been reported to inhibit fibrosis in myocardium, which does not have V2 receptors.(8)

The liver, like the myocardium, also does not have V2 receptors.(9) Thus, we examined tolvaptan monotherapy and combination therapy with furosemide in a rat cirrhotic model for their usefulness in inhibiting hepatic fibrosis.

Materials and Methods

Animals. Animals were reared in accordance with the Yamaguchi University Graduate School of Medicine’s ethical guidelines on the use of animals. Six-week-old male Wistar rats (140–160 g) were purchased from Japan SLC (Shizuoka, Japan) and maintained in a room at an animal experiment facility at the Yamaguchi University Graduate School of Medicine under controlled temperature (25°C) and lighting (12-h light/12-h dark) conditions. The rats were fed a powdered choline-deficient l-amino-acid-defined (CDAA) diet (Dyets Inc., Bethlehem, PA; product numbers 518753, 518754) and injected intraperitoneally 10 mg/kg diethylnitrosamine (DEN) (Sigma N0756) weekly for 16 weeks.

Drug administration. The entire experiment was conducted over a course of 16 weeks. The drugs used were furosemide (Otsuka Pharmaceutical Co., Ltd., Toyama, Japan) and tolvaptan (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). The rats were divided into five groups (n = 7 per group): a low-dose furosemide group (15 mg/kg/day; F15 group), a high-dose furosemide group (100 mg/kg/day; F100 group), a tolvaptan monotherapy group (10 mg/kg/day; T10 group), a low-dose furosemide + tolvaptan combination therapy group (F15 + T10; F15T10 group), and a control group in which neither drug was administered (C group). The drugs were mixed with the CDAA diet and administered continuously for 16 weeks. The rats were allowed ad libitum access to water. Urine volume in all groups was measured 4 h after drug administration.

Blood measurements. To obtain serum samples, the rats were euthanized, and blood was collected from the celiac artery. We measured total serum protein, albumin, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), LDH,
Creatinine, urea nitrogen, sodium, potassium, and chloride.

**Histological and immunohistochemical examinations.** Sections of the right lobe of the liver (around 3 mm thick) were harvested from all rats, fixed in paraformaldehyde for 24 h, and embedded in paraffin. These sections were stained with Sirius red to assess hepatic fibrosis. Immunostaining was performed with anti-alpha-smooth muscle actin (α-SMA) antibody to identify activated stellate cells and 8-hydroxy-2'-deoxyguanosine (8-OHdG) antibody to assess oxidative stress; these assessments were conducted with the avidin-biotin-peroxidase technique as described below. (9)

Briefly, 3-μm-thick tissue sections were deparaffinized in xylene and rehydrated with alcohol and water. Antigens were retrieved by heating in a microwave oven 10 mM citrate buffer (pH 6.0) containing the tissue sections at 95°C for 6 min. Endogenous peroxidase was blocked with methanol solution containing 0.3% hydrogen peroxide at room temperature for 30 min. Non-specific reactions were blocked with rabbit serum (Vector Laboratories, Burlingame, CA) for 20 min. Primary antibody reaction was performed on the sections overnight at 4°C in a moist chamber with rabbit polyclonal α-SMA antibody (1:50) (ab7817; Abcam, Cambridge, MA) and anti-8-OHdG antibody (1:100) (N45.1; JaICA, Shizuoka, Japan). The sections were then washed with phosphate-buffered saline (PBS) three times and reacted with biotinylated secondary antibody at room temperature for 1 h. Bound antibodies were detected with the avidin-biotin-peroxidase complex (ABC) technique (Vector Laboratories).

The Sirius red-positive, α-SMA-positive areas of the liver sections were visualized using a Keyence BIOREVO BZ9000 microscope (Osaka, Japan) and a Provis microscope (Olympus, Tokyo, Japan) equipped with a charge-coupled device (CCD) camera. Computer-assisted image analysis was performed with MetaMorph software (Universal Imaging Corporation, Downingtown, PA). The Sirius red-positive, α-SMA-positive areas were displayed as percentages of the total surface area of the specimens. Numbers of 8-OHdG-positive cells were counted in each section using a Keyence BIOREVO BZ9000 microscope.

**Table 1. Characteristics at the end of 16 weeks**

|               | C (n = 7)  | F15 (n = 7) | T10 (n = 7) | F15T10 (n = 7) | F100 (n = 7) |
|---------------|-----------|------------|------------|----------------|-------------|
| **Body weight (g)** | 273.4 ± 7.7 | 267.5 ± 18.5 | 271.7 ± 18.5 | 273.0 ± 17.4 |             |
| **Liver weight (g)** | 23.8 ± 0.3 | 19.5 ± 1.6** | 20.1 ± 1.6** | 19.1 ± 1.7** |             |
| **Urine volume (ml/kg/4 h)** | 4.5 ± 1.7 | 11.0 ± 2.2** | 24.0 ± 3.2** | 28.0 ± 6.2** | 26.5 ± 5.9** |
| **Serum** |          |            |            |                |             |
| T.Bil (mg/dl) | 0.40 ± 0.11 | 0.23 ± 0.15** | 0.28 ± 0.15** | 0.25 ± 0.16** |             |
| AST (IU/L) | 389.8 ± 32.4 | 360.7 ± 57.9 | 335.0 ± 20.1** | 293.7 ± 44.5** |             |
| ALT (IU/L) | 400.5 ± 68.9 | 383.1 ± 126.7 | 384.6 ± 26.2 | 335.1 ± 79.7 |             |
| LDH(IU/L) | 2103.5 ± 175 | 2090.7 ± 777 | 1793.3 ± 311 | 1844 ± 713 |             |
| CRE (mg/dl) | 0.33 ± 0.05 | 0.37 ± 0.07 | 0.27 ± 0.02* | 0.36 ± 0.09 |             |
| BUN (mg/dl) | 16.3 ± 3.7 | 15.9 ± 1.7 | 17.5 ± 2.3 | 20.4 ± 2.1* |             |
| Na (mEq/L) | 143.2 ± 0.7 | 143.9 ± 0.7 | 144.1 ± 1.5 | 143.7 ± 1.0 |             |
| K (mEq/L) | 4.7 ± 0.4 | 4.8 ± 0.5 | 4.8 ± 0.5 | 4.5 ± 0.4 |             |
| Cl (mEq/L) | 102.0 ± 1.8 | 102.7 ± 1.3 | 101.7 ± 1.1 | 101.6 ± 1.0 |             |

Data are mean ± SD. **p<0.05 vs C group. ***p<0.01 vs C group.
T10, and F15T10 groups demonstrated a significant decrease in total bilirubin levels, as well as a tendency towards a decrease in ALT levels.

However, the F100 group demonstrated a marked increase in serum creatinine levels (1.30 ± 0.37 mg/dl) at 7 weeks; in the one rat that survived for 16 weeks, serum creatinine level was markedly high at 2.2 mg/dl.

**Histological and immunohistochemical examinations.**

At 16 weeks, histological and immunohistochemical analyses of the liver revealed hepatic fibrosis in all groups. Compared to the C group, the Sirius red-positive area was significantly smaller in the treatment groups. No significant differences were observed among the treatment groups. Although the positive region was smaller in the F15T10 group, the difference was not statistically significant (Fig. 2).

Rats administered CDAA + DEN demonstrated marked proliferation of activated hepatic stellate cells, as observed by α-SMA staining. The treatment groups demonstrated significant reductions in α-SMA area compared to the control group. No significant differences were observed among the treatment groups (Fig. 3).

The number of cells positive for staining by 8-OHdG, a marker of oxidative DNA damage, was significantly lower in the treatment groups (Fig. 4).

**Effects on gene expression related to hepatic fibrosis.**

We analyzed collagen I, TGF-β1, TIMP-1, and α-SMA mRNA expression in rat livers at 16 weeks. Expression of these transcripts was significantly inhibited in the treatment groups (Fig. 5).

**Antioxidative effect of tolvaptan.**

To assess the effect of tolvaptan on oxidative stress, we used HepaRG cells, which are reported to demonstrate human hepatocyte-like morphology and to retain and express the functions of human hepatocytes.(10,11)

Exposure of HepaRG cells to 150-μM tert-BHP for 24 h resulted in the death of approximately 40% of the cells. Compared to the administration of only tert-BHP, co-administration of 0.1–5 μM tolvaptan resulted in significant inhibition of cell death. No significant differences were observed with administration of ≥10 μM tolvaptan (Fig. 6).

**Discussion**

Hepatic edema occurs when cirrhosis advances and becomes decompensated. Conventionally, hepatic edema has been treated with aldosterone drugs and loop diuretics; however, these sometimes fail to yield sufficient effects despite increase in dose or combined administration.(3) In addition, higher doses and combined administration may upset the balance of electrolytes in the blood and impair renal function.(12) For example, patients with cirrhotic ascites treated with furosemide have been reported to demonstrate significantly increased serum creatinine levels and BUN concentration, as well as significantly decreased glomerular filtration rate.(13,14) Furthermore, by binding to albumin in blood, furosemide is secreted in the renal tubular lumen and is transported to the site of action, thereby resulting in insufficient action associated with hypoalbuminemia. Renal impairment and hyponatremia is associated with a poor prognosis for cirrhosis.
Awareness has recently increased regarding the importance of renoprotection in cirrhosis. Because tolvaptan exhibits a diuretic effect without causing excretion of sodium, it may be used in combination therapy to treat fluid retention in cirrhosis when existing diuretics fail to achieve a sufficient therapeutic effect. Tolvaptan exerts its effect irrespective of serum albumin levels; thus, significant reduction in body mass has also been observed in patients with hypoalbuminemia. Tolvaptan causes water diuresis leading to an increase in intravascular sodium levels and migration of extravascular water into the blood vessels, thereby retaining water in the blood vessels; this increases renal blood flow and prevents renal impairment. Long-term tolvaptan therapy in rat models of end-stage heart failure has been reported to improve kidney function, glomerular sclerosis, and interstitial fibrosis associated with oxidative stress.

Hence, we examined the usefulness of tolvaptan monotherapy and combination therapy with furosemide in livers, which have no V2 receptors, of a rat cirrhotic model. In the present study, we fed rats a CDAA diet, which triggered reactive oxygen species-related hepatocellular injury leading to hepatic fibrosis. Oxidative stress has also been demonstrated to play a major role in the progression of hepatitis C and non-alcoholic steatohepatitis. In hepatitis C, production of reactive oxygen species is reported to be enhanced.

Fig. 3. Immunohistochemical analysis of alpha-smooth muscle actin (α-SMA) expression in hepatic fibrosis. Paraffin-embedded rat liver sections were stained with α-SMA (40× magnification). (a) CDAA + DEN only group, (b) CDAA + DEN + 15 mg/kg/day furosemide group, (c) CDAA + DEN + 10 mg/kg/day tolvaptan group, (d) CDAA + DEN + 15 mg/kg/day furosemide + 10 mg/kg/day tolvaptan group. (e) Image analysis of α-SMA-positive areas. Data are presented as mean ± SD. *p<0.05 vs CDAA + DEN group.

Fig. 4. Immunohistochemical analysis of 8-hydroxy-2′-deoxyguanosine (8-OHdG) expression. Paraffin-embedded rat liver sections were immunostained with 8-OHdG (40× magnification). (a) CDAA + DEN only group, (b) CDAA + DEN + 15 mg/kg/day furosemide group, (c) CDAA + DEN + 10 mg/kg/day tolvaptan group, (d) CDAA + DEN + 15 mg/kg/day furosemide + 10 mg/kg/day tolvaptan group. (e) Image analysis of 8-OHdG-positive cells. Data are presented as mean ± SD. *p<0.01 vs CDAA + DEN group.
steatohepatitis, oxidative stress is reported to trigger production of inflammatory cytokines, which cause inflammation and fibrosis reaction. (21)

Tolvaptan has been reported to inhibit fibrosis in ventricular remodeling in rat models of acute and chronic myocardial infarction. (6,7) Thus, tolvaptan has been shown to inhibit fibrosis in myocardium, which does not have V2 receptors. In addition, tolvaptan has been demonstrated to exert anti-inflammatory action

Fig. 5. Real-time quantitative PCR analysis. (a) alpha-smooth muscle actin (α-SMA), (b) type I procollagen (Col I), (c) tumor growth factor beta (TGF-β1), (d) tissue inhibitor of metalloproteinase 1 (TIMP-1). Data are presented as mean ± SD. *p<0.05, **p<0.01 vs CDA2 + DEN group.

Fig. 6. Tolvaptan demonstrated an antioxidative effect on tert-BHP-induced oxidative stress. MTS assay in HepaRG cells. Viability of HepaRG cells without drug administration was treated as 100%. Administration of tert-BHP alone caused the death of 40% of the cells. Tolvaptan was administered at concentrations of 0–80 μM. Data are presented as mean ± SD. *p<0.01 vs tolvaptan 0 μM.
and inhibit expression of TGF-β1 and collagen I mRNA. In the present study, low-dose furosemide, tolvaptan, and a combination of the two were found to reduce expression of α-SMA, collagen I, TGF-β1, and TIMP-1 mRNA; to reduce α-SMA-positive activated hepatic stellate cells; and to inhibit fibrosis in the liver. In blood chemistry analysis, tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy were found to significantly increase albumin, significantly reduce AST, and yield a hepatoprotective effect. In addition, these therapies and low-dose furosemide monotherapy were found to result in a tendency towards reduced ALT and total bilirubin. The significant decrease in liver mass did not cause any difference in hepatic fat mass (data not shown) and was thus considered to reflect a hepatoprotective effect against hepatic dysfunction caused by CDAA diet + DEN.

In addition, tolvaptan monotherapy, low-dose furosemide monotherapy, and low-dose furosemide/tolvaptan combination therapy were found to reduce numbers of 8-OHdG positive cells, which reflect the degree of DNA oxidative stress in the liver. Treatment of HepaRG cells with tolvaptan led to an antioxidative effect under oxidative stress induced by tert-BHP. The antioxidative effect may be the mechanism by which tolvaptan exerts its hepatoprotective effects. To our knowledge, the present study is the first to assess the antioxidative effect of tolvaptan on hepatocytes.

An increase in serum renin activity triggered by furosemide results in the activation of the renin-angiotensin-aldosterone system, which may paradoxically enhance hepatic fibrosis. However, 10 mg/kg/day furosemide does not increase serum renin activity; thus, the low dose of furosemide used in the present study may have been insufficient to activate the renin-angiotensin-aldosterone system. In addition, furosemide is reported to exert an antioxidative effect and a hepatoprotective effect, which were obtained with low-dose furosemide.

Tolvaptan is also used in clinical settings to treat autosomal dominant polycystic kidney disease. Although our study demonstrated that tolvaptan exerts a hepatoprotective effect, serious liver damage has also been reported. This potential for liver damage is shown) and was thus considered to reflect a hepatoprotective effect against hepatic dysfunction caused by CDAA diet + DEN. However, high-dose furosemide was found to result in marked renal impairment from an early stage and lead to a high death rate.

In the present study, not only tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy, but also low-dose furosemide monotherapy demonstrated equivalent effects in terms of hepatoprotection. However, low-dose furosemide monotherapy failed to yield sufficient urinary output.

Prior to the approval of tolvaptan, when treatment of fluid retention due to cirrhosis with spironolactone and furosemide failed to achieve appreciable therapeutic effects, the only recourse was to increase the doses. Currently, in Japan, tolvaptan is used in combination with existing diuretics. The results of the present study suggest that it is important to introduce tolvaptan from an early stage of low-dose furosemide administration than increase the dosage of furosemide. Although further investigation is necessary, the present study suggests that tolvaptan monotherapy may be highly useful.

Tolvaptan administration is 60–120 mg/day; administration of 7.5 mg/day was within the range of tolvaptan concentrations that demonstrated a renoprotective effect. However, low-dose furosemide monotherapy failed to yield sufficient urinary output.

Deterioration of kidney function was not observed in the low-dose furosemide monotherapy group, or the low-dose furosemide/tolvaptan combination therapy group in comparison to the control group. The tolvaptan monotherapy group demonstrated a significant decrease in serum creatinine; as reported in a previous study, tolvaptan may exert a renoprotective effect.

Urine volume, the fundamental purpose of administering diuretics, was significantly larger in the treatment groups than in the control group. In addition, urinary output was further higher in the T10, F100 and F15T10 groups than in the F15 group. However, high-dose furosemide was found to result in marked renal impairment from an early stage and lead to a high death rate. Although no kidney damage was observed in the F15 group, urine volume was insufficient. In the T10 and F15T10 groups, no kidney damage was observed, and unlike the F15 group, urine volume was sufficient.

In the present study, not only tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy, but also low-dose furosemide monotherapy demonstrated equivalent effects in terms of hepatoprotection. However, low-dose furosemide monotherapy failed to yield sufficient urinary output.

No potential conflicts of interest were disclosed.

Acknowledgments
We thank Ms. M. Yamada, Ms. I. Fujimoto, Ms. K. Ota, Ms. H. Kurose and Ms. R. Mochizuki for their technical assistance.

Abbreviations
α-SMA α-smooth muscle actin
ALT alanine aminotransferase
AST aspartate aminotransferase
CDAA choline-deficient L-amino acid
DEN diethylnitosamine
DMSO dimethyl sulfoxide
8-OHdG 8-hydroxy-2′-deoxyguanosine
tert-BHP tert-butyl hydroperoxide
TGF-β1 tumor growth factor beta1
TIMP-1 tissue inhibitor of metalloproteinase 1

Conflict of Interest
No potential conflicts of interest were disclosed.

References
1 Solà E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012; 57: 1199–1206.
2 Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17: 163–173.
3 Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol 2012; 27: 11–20.
4 Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis 2011; 4: 57–71.
5 Sakaia I, Kawaoze S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014; 44: 73–82.
6 Yamazaki T, Izumi Y, Nakamura Y, et al. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail 2012; 5: 794–802.
7 Yamazaki T, Nakamura Y, Shiota M, et al. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci 2013; 123: 58–66.
8 Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1–8.
9 Saeki I, Terai S, Fujisawa K, et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol 2013; 48: 738–750.

doi: 10.3164/jcbn.16-122
©2017 JCBN
10 Parent R, Marion MJ, Furio L, Trépo C, Petit MA. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 2004; 126: 1147–1156.
11 Cerec V, Glaize D, Garnier D, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007; 45: 957–967.
12 Cárdenas A, Arroyo V. Refractory ascites. Dig Dis 2005; 23: 30–38.
13 Bernardi M, De Palma R, Trevisani F, Santini C, Servadei D, Gasbarrini G. Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis. Z Kardiol 1985; 74 Suppl 2: 129–134.
14 Ginés P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhosis with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234–241.
15 Fede G, D’Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810–818.
16 Iwasa M, Ishihara T, Hasegawa H, Takei Y. Cirrhosis-related hyponatremia and the role of tolvaptan. Hepatol Res 2015; 45: E163–E165.
17 Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol 2015; 50: 1047–1053.
18 Ishikawa M, Kobayashi N, Sugiymama F, Onoda S, Ishimitsu T. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int Heart J 2013; 54: 98–106.
19 Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999; 44: 560–569.
20 Valgimigli L, Valgimigli M, Gaiani S, Pedulli GF, Bolondi L. Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radic Res 2000; 33: 167–178.
21 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59–69.
22 Hirano T, Yamamura Y, Nakamura S, Omogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288–294.
23 Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34 (4 Pt 1): 745–750.
24 Lahet JJ, Lenfant F, Courderot-Masuyer C, et al. In vivo and in vitro antioxidant properties of furosemide. Life Sci 2003; 73: 1075–1082.
25 Kang MY, Tsuchiya M, Packer L, Manabe M. In vitro study on antioxidant potential of various drugs used in the perioperative period. Acta Anaesthesiol Scand 1998; 42: 4–12.
26 Wu Y, Beland FA, Chen S, Liu F, Guo L, Fang J. Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol 2015; 95: 324–336.
27 Sakaida I, Yanase M, Kobayashi Y, Yasukata T, Okada M, Okita K; ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res 2012; 40: 2381–2393.